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ABSTRACT
Background: The putative functional variant −265T>C (rs5082)
within the APOA2 promoter has shown consistent interactions with
saturated fatty acid (SFA) intake to influence the risk of obesity.
Objective: The aim of this study was to implement an integrative
approach to characterize the molecular basis of this interaction.
Design: We conducted an epigenome-wide scan on 80 participants
carrying either the rs5082 CC or TT genotypes and consuming ei-
ther a low-SFA (<22 g/d) or high-SFA diet (≥22 g/d), matched for
age, sex, BMI, and diabetes status in the Boston Puerto Rican Health
Study (BPRHS). We then validated the findings in selected partic-
ipants in the Genetics of Lipid Lowering Drugs and Diet Network
(GOLDN) Study (n = 379) and the Framingham Heart Study (FHS)
(n= 243). Transcription and metabolomics analyses were conducted
to determine the relation between epigenetic status, APOA2 mRNA
expression, and blood metabolites.
Results: In the BPRHS, we identified methylation site cg04436964
as exhibiting significant differences between CC and TT participants
consuming a high-SFA diet, but not among those consuming low-
SFA. Similar results were observed in the GOLDN Study and the
FHS. Additionally, in the FHS, cg04436964 methylation was nega-
tively correlated with APOA2 expression in the blood of participants
consuming a high-SFA diet. Furthermore, when consuming a high-
SFA diet, CC carriers had lower APOA2 expression than those with
the TT genotype. Lastly, metabolomic analysis identified 4 pathways
as overrepresented by metabolite differences between CC and TT
genotypes with high-SFA intake, including tryptophan and branched-
chain amino acid (BCAA) pathways. Interestingly, these pathways
were linked to rs5082-specific cg04436964 methylation differences
in high-SFA consumers.
Conclusions: The epigenetic status of the APOA2 regulatory region
is associated with SFA intake and APOA2−265T>C genotype, pro-
moting an APOA2 expression difference between APOA2 genotypes
on a high-SFA diet, andmodulating BCAA and tryptophanmetabolic
pathways. These findings identify potential mechanisms by which
this highly reproducible gene-diet interaction influences obesity risk,
and contribute new insights to ongoing investigations of the relation
between SFA and human health. This studywas registered at clinical-
trials.gov as NCT03452787. Am J Clin Nutr 2018;108:188–200.
Keywords: APOA2, epigenomics, metabolomics, transcription,
gene-diet interaction, obesity, tryptophan metabolism, branched-
chain amino acid metabolism, satiety
INTRODUCTION
A common genetic variant within the promoter of apolipopro-
tein A-II gene (APOA2), −265T >C (rs5082), with a frequency
of the minor C allele ranging from 0.2 to 0.4, depending on
the population, directs APOA2 expression in vitro (1). Genetic
studies in humans have shown associations with obesity and
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postprandial metabolism of triglyceride-rich lipoprotein (1, 2).
While this single nucleotide polymorphism (SNP)was not associ-
ated with obesity in genome-wide studies, we have demonstrated
that this variant interacts with SFA intake on risk of obesity in
several populations in the United States, Europe, and Southeast
Asia (3–7). Individuals with the CC genotype have an elevated
obesity risk when consuming a diet high in SFA (i.e., ≥22 g/d)
(3, 6), compared with T allele carriers. In addition, CC carriers
tend to consume more food, and particularly more high-fat and
high-protein foods (7). Despite these consistent observations, the
molecular mechanisms underlying this gene-by-diet interaction
on obesity remain unknown.
Epigenetic status reflects an individual’s profile acquired in re-
sponse to environmental exposures (8). Early life nutrition, adult
lifestyle habits, and other environmental factors can “program”
disease risk in later life (9). Gene-diet interactions may reflect, in
part, the effects of diet on epigenetic status. Epigenetic changes
in promoter and enhancer regions can differentially affect mRNA
expression of target genes, modifying their expression and, thus,
regulation of specific metabolic pathways, which can be detected
through metabolomic analysis (10).
Importantly, APOA2 CC homozygotes exhibited an increased
risk of obesity only when consuming a high-SFA diet, but they
have no increased risk of obesity when consuming a low-SFA diet
(4–8). This observation suggests that higher SFA intake occurs
first, followed by APOA2 genotype–associated obesity. Thus, we
hypothesized that the genotype-dependent response to a high-
SFA diet could involve epigenetic changes, leading to altered
APOA2 expression and metabolic changes in energy metabolism
and homeostasis. In this study, we examined the correlation be-
tween epigenome-wide variation and APOA2 genotype, condi-
tional on dietary SFA intake, in selected participants of the Boston
Puerto Rican Health Study (BPRHS), and then validated our find-
ings in 2 additional populations, the Framingham Heart Study
(FHS) and the Genetics of Lipid Lowering Drugs and Diet Net-
work (GOLDN) Study. In the FHS, we further examined how
the identified methylation site within the APOA2 region affects
APOA2 mRNA expression across different APOA2 genotypes
and varying SFA intakes. We then investigated differences in
metabolomic profiles between CC and TT genotypes in relation
to low- or high-SFA intake in order to understand the relation be-
tween epigenetic signatures and metabolic pathways in the con-
text of obesity risk. This study was designed to identify potential
mechanisms by which this highly reproducible gene-diet inter-
action influences obesity risk, and also inform the long-standing
debates surrounding saturated fat intake and health outcomes.
METHODS
Boston Puerto Rican Health Study
The BPRHS is a longitudinal cohort study (11). The primary
objective is to examine and characterize the relations between nu-
trition, genetics, and health disparities in Puerto Rican adults. The
population comprises 1499 individuals, self-identified as Puerto
Ricans, with baseline age ranging from 45 to 75 y (11). To max-
imize the power to detect the effect of the C allele, we designed
the study to focus on the difference between 2 homozygotes (CC
compared with TT), which we expected to be maximal. Based on
our published observations of the APOA2-SFA interaction, which
was consistent in several populations (3–6) and an epigenome-
wide association study (12), we determined that a sample size of
20 for each CC and TT genotype with either low- or high-SFA has
statistical power of 95% to detect epigenetic signatures at a sig-
nificance of α = 1.1 × 10−7 (1% methylation difference between
CC and TT genotype and an SE of 0.2%) of the APOA2-SFA in-
teraction on obesity.Within this study (see Supplemental Figure
1), 40 participants with CC genotype at APOA2 −265T>C were
selected, with 20 reporting a low-SFA intake (<22 g/d) and 20
reporting a high-SFA intake (≥22 g/d) (3, 6). By matching age,
sex, SFA intake, type 2 diabetes status, and BMI for the 40 partic-
ipants with CC genotype, the second set of 40 participants with
TT genotype at APOA2 −265T>C was selected from the same
population, with priority given to participants who were matched
most closely for age, sex, SFA intake, and type 2 diabetes
(Table 1). The Institutional Review Board at Tufts University ap-
proved the study protocol. All participants provided written con-
sent for participation in the study.
Genetics of Lipid Lowering Drugs and Diet Network Study
The GOLDN Study is a constituent of the Family Heart Study
within the NIH National Heart, Lung and Blood Institute (7).
Participants (n = 1327), aged ≥18 y, from US families of Eu-
ropean descent, were recruited at 2 field centers: Minneapolis,
MN and Salt Lake City, UT. The main goal of the GOLDN
Study was to identify genetic factors that determine individ-
ual responses to high-fat meals and 3-wk treatment with fenofi-
brate, a triglyceride-lowering medication (12). Institutional Re-
view Boards at Tufts University, the University of Minnesota,
University of Utah, and the University of Alabama at Birming-
ham approved the study protocol. In the current study (see Sup-
plemental Figure 2), 107 participants with CC genotype and 272
with TT genotype for APOA2 −265T>C, who were not taking
medication for hypertension, dyslipidemia, or diabetes, were se-
lected to validate the findings from the BPRHS. Participants of
each genotype were further divided into 2 subgroups, based on
low-SFA (<22 g/d) and high-SFA intake (≥22 g/d) (Table 1)
(3, 6).
Framingham Heart Study
Established in 1948, the FHS is a free-living multiple genera-
tion study of participants recruited in and near Framingham, MA
(13). The Offspring Cohort started in 1971 with the enrollment of
5124 participants recruited from the children and spouses of the
original FHS (14). In-person physical and clinical examinations
occurred every 4–8 y. In exam 8, 2005–2008, blood samples were
collected, and 2741 samples were available for DNA methylome
and transcriptome analysis (15). In this study (see Supplemen-
tal Figure 3), to validate the findings from the BPRHS, we in-
clude 73 unrelated participants with CC genotype and 170 with
TT genotype at APOA2 −265T >C who did not take medication
for hypertension, dyslipidemia, or diabetes. Participants of each
genotype were further divided into 2 subgroups based on SFA
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TABLE 1
Characteristics of participants in 3 populations according to CC and TT genotypes of APOA2 –265T >C1
TT CC
Low-SFA intake High-SFA intake Low-SFA intake High-SFA intake
BPRHS
n = 80 20 20 20 20
Women, % 50 50 50 50
Age, y 59.5 ± 6.8 59.6 ± 6.8 59.5 ± 6.7 58.6 ± 7.6
Drinker, % 30 60 35 60
Smoker, % 10 25 35 30
BMI, kg/m2 31.6 ± 5.8 31.2 ± 5.6 29.4 ± 6.0 34.0 ± 5.72
SFA, g/d 14.0 ± 4.2 33.7 ± 8.62 14.6 ± 5.0 35.1 ± 12.62
Total energy, kcal 1699 ± 561 3000 ± 6302 1522 ± 416 2932 ± 6912
GOLDN
n = 379 107 165 39 68
Women, % 77 42 85 40
Age, y 46.3 ± 16.8 41.5 ± 14.0 43.8 ± 15.8 43.4 ± 12.7
Drinker, % 47 45 64 54
Smoker, % 26 26 31 29
BMI, kg/m2 27.9 ± 5.5 26.8 ± 5.0 27.1 ± 5.4 29.1 ± 5.9
SFA, g/d 15.3 ± 4.5 38.0 ± 20.82 15.9 ± 4.0 41.1 ± 19.52
Total energy, kcal 1351 ± 383 2599 ± 14072 1367 ± 402 2884 ± 12082
FHS
n = 243 74 96 34 39
Women, % 73 56 71 62
Age, y 65.1 ± 9.3 62.1 ± 8.2 65.4 ± 9.4 64.4 ± 7.7
Drinker, % 76 72 91 82
Smoker, % 12 4 6 10
BMI, kg/m2 25.3 ± 4.2 27.5 ± 5.42 25.4 ± 3.7 26.7 ± 4.5
SFA, g/d 16.1 ± 4.2 31.6 ± 9.22 15.9 ± 4.3 30.6 ± 7.62
Total energy, kcal 1532 ± 349 2284 ± 5122 1528 ± 337 2336 ± 5372
1Age, BMI, SFA, total energy are expressed as means± SDs. APOA2, apolipoprotein A-II; BPRHS, Boston Puerto Rican Health Study; FHS, Framingham
Heart Study; GOLDN, Genetics of Lipid Lowering Drugs and Diet Network.
2Significant differences by t test between high- and low-SFA in participants with CC or TT genotype.
Assessment of dietary intake
In the BPRHS, diet was assessed using a specially designed
and validated food frequency questionnaire (16), whereas the
Diet History Questionnaire was administrated in the GOLDN
Study (17) and theWillett semi-quantitative food frequency ques-
tionnaire was applied in exam 8 of the FHS (18). The dietary in-
take for each population (16–18) was estimated based on the Har-
vard University food composition database, the US Department
of Agriculture database, and the Minnesota Nutrient System.
DNA extraction
In the BPRHS and the FHS, genomic DNA for methylation
analysis was extracted from buffy coats using the QIAamp DNA
Blood mini kit or Gentra Puregene DNA extraction kit (Qiagen)
(15). In the GOLDN Study, genomic DNA was isolated from
CD4+ T cells from frozen buffy coat samples using DNeasy kits
(Qiagen) (12).
Methylome analysis
Genome-wide DNA methylation of isolated DNA samples in
the BPRHS and the GOLDN Study was quantified using Illu-
mina Infinium human methylation 450K arrays (Illumina), as
described previously (15, 19). The methylation signal at each
methylation site was estimated as a β score, the proportion of
the total methylation-specific signal, and the detection P value
was the probability that the total intensity for a given probe fell
within the background signal intensity.Methylation sites were ex-
cluded from further analysis if one of the following criteria was
met: 1) detection P > 0.01 and 1.5% of samples have missing
data, or 2) >10% of samples lack sufficient intensity (12). The
methylation signal β scores were further adjusted for batch ef-
fects across samples and normalized using the ComBat function
in the ChAMP R package (20). To account for heterogeneity of
different cell types across all samples, principal components were
calculated, based on the β scores of all autosomal CpG sites that
passed quality control, using the prcomp function in R (v12.12.1).
The first 4 principal components were used in all subsequent sta-
tistical analyses.
We acquired the FHS DNA methylome data through dbGaP,
accession #phg000492.v2, where the methylation statuses of
2741 participants were measured at exam 8, using Illumina In-
finium human methylation 450K arrays (15). Methylation sig-
nals were processed and normalized as for the BPRHS and the
GOLDN Study.
Transcription analysis
We obtained FHS transcriptome data from dbGaP under ac-
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exam 8 using the Affymetrix Human Exon 1.0 ST array with
mRNA from whole blood samples collected from 725 Offspring
Cohort participants after overnight fasting (21). The quality con-
trol and normalization of the initial gene expression data have
been published elsewhere (22, 23). In this study, we extracted
gene expression data for 201 of 243 participants with CC or TT
genotypes who were not taking medication for hypertension, dys-
lipidemia, or diabetes. Furthermore, to determine if the identified
methylation site (i.e., cg04436964) was correlated with gene ex-
pression of APOA2 or nearby genes, we focused analysis on the
expression of those 10 genes that passed quality control (QC) of
the 31 genes that map within 50 kb upstream or downstream of
the identified methylation site. Genes present on the array but not
passing QC can be considered as unresponsive to methylation at
cg04436964.
Metabolomic profile
Metabolic profiling of plasma samples from those 80 partic-
ipants of the BPRHS for whom the methylome analysis was
performed was conducted by Metabolon, Inc. (24). Briefly, 80
plasma samples were shipped on dry ice to Metabolon, and
stored at −80°C until analysis. After proteins were removed with
methanol, metabolomic analysis was performed using ultrahigh-
performance liquid chromatography-tandem mass spectroscopy.
With reference to a library of over 4500 purified standards for
retention time/index, mass-to-charge ratio, and chromatographic
data, individual metabolites were identified and quantified by
estimating the AUC of the peaks. A total of 808 metabolites that
passed QC were identified and assigned to pathway groups.
Statistical analysis
A schematic of the data analysis with sample size information
is depicted in Figure 1.
Epigenome-wide analysis of APOA2 genotype, by high- and
low-SFA intake, in the BPRHS
To identify epigenetic sites that differed between APOA2
−265T>C CC and TT genotypes, we conducted an epigenome-
wide association study in 80 participants selected according to
their genotype using the GEM package R tool suite, with methy-
lation signals as dependent variables with the G-model (detecting
methylation markers associated with genotype, i.e., methylation
quantitative trait loci) (25), adjusting for medication for hyper-
tension, lipid-lowering, cell-type heterogeneity, and population
structure. Population structure was adjusted by principle compo-
nent analysis (PCA), with 50,704 selected SNPs genotyped us-
ing Affymetrix Axiom World LA Arrays, designed especially
for Hispanic populations, and probe sets to genotype 817,810
SNPs. The 50,704 SNPs were selected based on call rate >97%,
MAF ≥5%, pairwise linkage disequilibrium R2 ≤ 0.1, and P
value of the Hardy-Weinberg Equilibrium ≥10−6. Using PCA
FIGURE 1 Analysis scheme. Experiments, described in the leftmost column, proceeded from top to bottom. Cohort source and sample sizes for the
various genotypes at APOA2 −265T >C under conditions of low or high SFA intake are given. For all analyses involving the BPRHS cohort, data from
the same participants were used, and from the same data collection period. APOA2, apolipoprotein A-II; BPRHS, Boston Puerto Rican Health Study; FHS,
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implemented in SVS (GoldenHelix Inc.), one eigenvalue was se-
lected to represent population structure, based on the Scree plot.
This PCA1 principle component variable was used in all regres-
sionmodels to adjust for population structure. Total energy intake
was not included as a covariate in the linear regression model as
APOA2 −265T >C is known to be associated with total energy
intake (3). The Bonferroni correction with an epigenome-wide
significance of P = 1.1 × 10−7 was used to adjust for multiple
comparisons (12).
Validation in the GOLDN Study and the FHS
To validate the initial findings from the BPRHS, we conducted
a similar epigenome-wide association study in selected datasets
from the GOLDN Study (see Supplemental Figure 2) and from
the FHS (see Supplemental Figure 3). In the GOLDN Study, 271
participants with TT genotype and 107 participants of CC geno-
type who did not use medication for hypertension, dyslipidemia,
or diabetes were included in the validation analysis (Table 1 and
Supplemental Figure 2). To identify methylation quantitative trait
loci, a linear Gmodel was implemented with methylation mea-
sures as dependent variables and APOA2 genotype as a predic-
tor using the GEM package R tool suite (25), adjusting for age,
sex, center, cell-type heterogeneity, and family relationship. In
the FHS, 171 participants with TT genotype and 73 with CC
genotype, who did not take medication for hypertension, dyslipi-
demia, or diabetes, were included for validation (Table 1 and Sup-
plemental Figure 3). A similar linear G-model was implemented
using the GEMpackage R tool suite (25), controlling for cell-type
heterogeneity, age, and sex. All analyses were conducted using
R3.3.2, and the results were reviewed and formatted using the
genome tool of SVS 8.7.
Meta-analysis
A meta-analysis of the results from the 3 populations
was conducted using the meta R package (https://cran.r-
project.org/web/packages/meta/index.html). A comparison of al-
lelic effect (β) of APOA2−265T >C from the meta-analysis be-
tween low- and high-SFA intake was conducted with SAS 9.4
(SAS Inc.) using a t test.
Associations between epigenetic variants and APOA2mRNA
expression in the FHS
To determine whether identified methylation sites in the
APOA2 region were associated with APOA2 mRNA expression
in whole blood, we examined the correlation between the identi-
fied methylation site (cg04436964, which showed differential as-
sociation with APOA2 genotype and differed between low- and
high-SFA intake) and FHS exam 8 expression data for genes
located within a 50-kb region of the methylation site. Gene
expression measures were treated as dependent variables, and
methylation sites and APOA2 genotype were tested as predictors,
controlling for age, sex, and cell-type heterogeneity. These anal-
yses were conducted using a linear regression model with SAS
9.4 or SVS 8.7.
Metabolic pathway enrichment analysis
All detected metabolites (n = 808) were organized into
metabolic pathways based on the annotation database of
Metabolon Inc. Only pathways that contained ≥3 detected
metabolites were included in the pathway analysis. For each
metabolite, comparisons between CC and TT genotypes were
conducted for high- or low-SFA intake. These comparisons were
conducted using ANCOVA contrast in a 2-way ANOVA model,
which included the fixed effects and interaction terms of genotype
and SFA, adjusting for BMI. Themean square error for the overall
model was used in the calculation of the individual contrasts. The
number of metabolites that differ between CC and TT genotypes
atP≤ 0.05 was counted within each pathway.Metabolic pathway
enrichment between CC and TT genotypes was determined by z
score calculation for each pathway, separately for low- and high-
SFA intake, as: Z score = [r – n (R/N)]/{n (R/N)[1 – (R/N)][1
– (n – 1)/(N – 1)]} (26), where N = 635 is the total number of
metabolites detected in the metabolomic profiling that were in-
cluded in the 63 pathways, R is the total number of metabolites
significantly different between CC and TT genotypes within low-
or high-SFA intake, n is the total number of metabolites mea-
sured in a specific pathway, and r is the number of metabolites
significantly different between CC and TT genotypes within a
specific pathway. P values of Z scores were derived assuming a
normal distribution and 2-sided, and were then corrected for mul-
tiple testing by the Bonferroni test (P = 0.05/63, 0.0008).
Linking the epigenomic and metabolomic signatures
To uncover the connection between epigenomic status and
metabolic network, we conducted metabolic network enrichment
analysis in relation to the identified methylation site cg04436964,
which differed between CC and TT genotypes with a high-
SFA intake. We performed an association analysis between
cg04436964 and all metabolites using a linear regression model,
adjusting for age, sex, population structure, and cell-type hetero-
geneity. The cg04436964-associated (at P ≤ 0.05) metabolites
were evaluated for overlap with those that differed (at P ≤ 0.05)
between CC and TT genotypes under high-SFA intake. The
number of metabolites that met both criteria (associated with
cg04436964 at P ≤ 0.05 and differed between CC and TT geno-
types under high-SFA intake) were counted within each pathway.
z scores and P values were calculated as above for each of 63
pathways. The P values were corrected for multiple testing us-
ing a Bonferroni test. Missing data were excluded from all the
analyses.
RESULTS
Epigenome-wide association analysis of APOA2 stratified by
SFA intake in the BPRHS
The general characteristics of 2 groups of selected participants
with CC genotypes (n = 40) and low- (<22 g/d) or high-SFA in-
take (≥22 g/d) (3, 6) and 2 groups of participants with TT geno-
types (n = 40) matched to the CC group by SFA intake, age, and
sex are shown in Table 1. While the men:women ratio and age
are almost identical among the 4 groups, the mean BMI of the
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TABLE 2
CpG sites that show significant difference in methylation status between APOA2 genotypes according to saturated fat intake in 3 populations1
CC vs. TT
Low-SFA High-SFA
CpG site Chr:Position2 n β (SE) P value3 n β (SE) P value3
BPRHS cg04436964 1:161,167,745 20 0.031 (0.006) 1.22 × 10−6 20 0.035 (0.005) 4.35 × 10−8*
cg24429974 1:161,195,180 20 0.010 (0.006) 3.77 × 10−3 20 0.009 (0.008) 0.255
cg24847046 1:161,135,079 20 −0.009 (0.006) 0.185 20 −0.017 (0.006) 0.011
GOLDN cg04436964 1:161,167,745 146 0.009 (0.002) 1.59 × 10−3 233 0.013 (0.002) 1.02 × 10−10*
cg24429974 1:161,195,180 146 0.009 (0.002) 1.51 × 10−4 233 0.011 (0.002) 1.84 × 10−10*
cg24847046 1:161,135,079 146 −0.004 (0.003) 0.106 233 −0.007 (0.002) 2.51 × 10−4
FHS cg04436964 1:161,167,745 108 0.031 (0.004) 5.23 × 10−12* 135 0.040 (0.003) 1.21 × 10−25*
cg24429974 1:161,195,180 108 0.022 (0.003) 1.63 × 10−10* 135 0.021 (0.003) 3.33 × 10−12*
cg24847046 1:161,135,079 108 −0.013 (0.003) 3.38 × 10−6 135 −0.018 (0.003) 2.70 × 10−8*
1*P value ≤1.1 × 10−7. APOA2, apolipoprotein A-II; BPRHS, Boston Puerto Rican Health Study; FHS, Framingham Heart Study; GOLDN, Genetics of
Lipid Lowering Drugs and Diet Network.
2The physical position of CpG sites was based on the genome build 37.
3The threshold of epigenome-wide significance is P value ≤1.1 × 10−7.
of the low-SFA intake group. In addition, SFA and total energy
intake were significantly greater in the high-SFA groups than in
the low-SFA groups regardless of APOA2 genotype. These differ-
ences are expected, as the participants were selected unbiasedly
to represent APOA2 genotype and SFA intake on obesity (3).
To identify the epigenomic signatures of APOA2 by SFA in-
teraction, we conducted an epigenome-wide scan to compare the
methylation status of 20 participants with CC genotype and 20
participants with TT genotypes each stratified by low- or high-
SFA intake (Figure 1). The Manhattan plots and QQ plots of all
methylation sites are depicted in Supplemental Figures 4A and
B, and 5A and B. For participants with high-SFA intake (Supple-
mental Figure 4B), one CpG site, cg04436964, with methylation
ranging from 0.77 (77%) to 0.96 (96%), attained genome-wide
FIGURE 2 Close-up of the 81-kb genomic region surrounding the APOA2 −265T >C site (rs5082, the orange dot) of an epigenome-wide association
study with APOA2 −265T >C in the BPRHS, GRCh37/hg19 approximate coordinates: chr1:161,134,000–1,612,215,000. (A) Under low saturated fat intake
or <22 g/d (low-SFA), B) under high saturated fat intake or ≥ 22 g/d (high-SFA). The vertical axis displays the –log10(P value) of association, whereas
the horizontal axis displays the physical position of CpG sites and genes (genome build 37). Each blue dot depicts one CpG site. The dashed line indicates
the threshold of epigenome-wide significance at P = 1.1 × 10−7. ADAMTS4, a disintegrin and metalloproteinase with thrombospondin motifs 4; APOA2,
apolipoprotein A-II; BPRHS, Boston Puerto Rican Health Study; B4GALT3, Beta-1,4-Galactosyltransferase 3; FCER1G, Fc fragment of IgE receptor Ig;
NDUFS2, NADH:ubiquinone oxidoreductase core subunit S2; NR1I3, nuclear receptor subfamily 1 group I member 3; PPOX, protoporphyrinogen oxidase;
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significance at P = 4.35 × 10−8 between CC and TT genotypes
(Table 2). This CpG maps ∼25.7 kb from the APOA2 transcrip-
tion start site (TSS) and∼25.9 kb from−265T>C. The physical
map of the 50-kb region centered on APOA2−265T >C (Figure
2B) indicates the single methylation site that displayed signif-
icant differences between CC and TT genotypes. One copy of
the C allele is associated with a 3.5% increase in methylation at
cg04436964 under a high-SFA diet, assuming an additive model
for the epigenetic effect. For participants with low-SFA intake
(Figure 2A, Table 2, Supplemental Figures 4A and 5A), how-
ever, methylation at no other CpG site differed significantly be-
tween CC and TT genotypes after correction for multiple testing
(P> 1.1× 10−7). As obesity may influence epigenetic status, we
controlled for BMI and observed that the associations remained
consistent. Furthermore, a comparison of methylation under con-
ditions of high- and low-SFA intake within each genotype, CC
or TT, indicated that no methylation site showed an epigenome-
wide significant difference (between low- and high-SFA) within
genotype (P > 1.1 × 10−7, data not shown).
Validation of epigenetic signature of interaction between
APOA2 and SFA intake
To validate the initial finding that cg04436964methylation sta-
tus correlates with APOA2 −265T>C genotype when SFA in-
take is high in the BPRHS, we conducted in the GOLDN Study
an epigenome-wide association study similar to the BPRHS. The
general characteristics of 379 participants of either CC (n= 107)
or TT (n = 272) genotype from the GOLDN Study are listed in
Table 1, excluding those taking medication for hypertension, di-
abetes, or dyslipidemia. Similar to the BPRHS, in the GOLDN
Study, participants’ methylation at cg04436964 showed a signif-
icant difference between CC and TT genotypes with high-SFA
intake at P = 1.02 × 10−10 (Table 2). In addition, cg24429974,
1.5 kb distal to−265T>C, also exhibited a significant genotype-
specific methylation difference at P = 1.84 × 10−10 in par-
ticipants with high-SFA intake, and the significance of the
results remained after adjustment for BMI. These significant
associations between methylation sites and APOA2 genotype are
depicted for the 80 kb region around APOA2−265T >C in Sup-
plemental Figure 6B. One copy of the C allele reflects an in-
crease in methylation of 1.3% at cg04436964 with high-SFA
intake (Table 2), assuming an epigenetic effect of an additive
model. However, in GOLDN Study participants with low-SFA
intake (<22 g/d) (3, 6), these 2 methylation sites (cg04436964
and cg24429974) did not reach epigenome-wide significance be-
tweenCC and TT genotypes (Supplemental Figure 6A, β = 0.009
and 0.009, P = 1.59 × 10−3 and 1.51 × 10−4, respectively).
To strengthen the validation, we conducted an additional
epigenome-wide association study with CC and TT participants
in the FHS at exam 8 who were not taking medication for hy-
pertension, diabetes, or dyslipidemia. The general characteristics
of the participants are given in Table 1. Similarly, methylation
site cg04436964 showed greater significant differences between
CC and TT genotypes in participants with high-SFA intake than
with low-SFA intake (Supplemental Figure 7, β = 0.040 vs.
0.031, P = 1.21 × 10−25 vs. 5.23 × 10−12, Table 2). In compari-
son with cg04436964, cg24429974 showed a similar but weaker
genotype-related difference between FHS participants with low-
and high-SFA intake (Supplemental Figure 7, β = 0.021 vs.
0.022, P = 3.33 × 10−12 vs. 1.63 × 10−10, Table 2). In addition,
cg24847046, 58.6 kb from rs5028, showed a significant associ-
ation with APOA2 genotype in participants with low- or high-
SFA intake (Supplemental Figure 7, β = −0.013 vs. −0.018,
P= 3.38× 10−6 vs. 2.70× 10−8, Table 2). Even after adjustment
for BMI, the findings remained consistent in all 3 populations. To-
gether, each of the associations described in 3 distinct populations
for cg04436964 are directionally identical, reach epigenome-
wide significance thresholds, are dependent on SFA intake and
rs5028 genotype, and share robustness with the gene-diet inter-
action described for this variant.
Meta-analysis of methylation differences between CC and
TT genotypes
To combine the results on these populations, we conducted a
meta-analysis with a fixed-effect model and found that methy-
lation site cg04436964 showed a greater difference between CC
and TT genotypes in high-SFA intake (Figure 3B, β = 0.023,
95% CI: 0.020, 0.026, P = 9.22 × 10−47) than low-SFA intake
(Figure 3A, β = 0.015, 95%CI: 0.012, 0.018, P= 5.15× 10−18).
For cg24429974, the difference in methylation status between
CC and TT genotypes was less apparent between high- (Figure
3D, β = 0.014, 95% CI: 0.011, 0.017, P = 5.76 × 10−17) and
low-SFA intake (Figure 3C, β = 0.013, 95% CI: 0.010, 0.016,
P = 1.59 × 10−15). Similarly, the difference in methylation site
cg2487046 between CC and TT genotypes was less obvious be-
tween high- (Figure 3F, β = −0.011, 95% CI: −0.014, −0.008,
P= 1.29 × 10−11) and low-SFA intake (Figure 3E, β = −0.009,
95% CI: −0.013, −0.005, P = 1.87 × 10−5).
To determine differential methylation associated with both
SFA intake and −265T>C genotype, we compared the differ-
ence in the allelic effect of the C allele on 3 methylation sites
between low- and high-SFA intake. Using a t test, we found
that participants with the CC genotype and high-SFA intake had
0.8% greater methylation at cg04436964, on average, when com-
pared with participants with the TT genotype and low-SFA intake
(P= 0.041). For cg24429974 and cg24847046, however, the dif-
ference between high- and low-SFA intake was not statistically
significant (0.1% and−0.2%,P= 0.565 and 0.337, respectively).
Annotation of CpG cg04436964
Data available for human genome build 37 at genome.ucsc.edu
indicate that cg04436964 is a solitary CpG, with the nearest CpG
island annotated approximately 4.1 kb distant. This information
is corroborated by the absence of correlation inmethylation status
between this CpG and other regional CpGs (data not shown). The
cg04436964 CpG appears to be just within or on the edge of an
enhancer region, as determined by querying adipose, kidney, and
liver cell data at the WashU Epigenome Browser (27). This en-
hancer is not observed in all assays or cell types, but data indicate
overlap with binding sites for RXRA and ZBTB7A, both tran-
scription factors, with roles in the epigenetics of obesity and the
regulation of genes highly expressed in adipose, respectively (28–
30). However, data are lacking as to whether this region functions
as an enhancer under conditions driven by the diet, either habitual







niversity of Kentucky Libraries user on 14 February 2019
SIGNATURES OF THE APOA2-SATURATED FAT INTERACTION 195
FIGURE 3 Forest plots of meta-analysis of methylation differences at 3 methylation sites over 3 populations (BPRHS, GOLDN, and FHS) between CC
and TT genotypes according to low- and high-SFA intake. The summary of statistics (β, SE, 95% CI, P value) of the meta-analysis are listed on each panel: (A)
cg04436964 at low-SFA intake; (B) cg04436964 at high-SFA intake; (C) cg24429674 at low-SFA intake; (D) cg24429674 at high-SFA intake; (E) cg24847046
at low-SFA intake; (F) cg24847046 at high-SFA intake. BPRHS, Boston Puerto Rican Health Study; FHS, Framingham Heart Study; GOLDN, Genetics of
Lipid Lowering Drugs and Diet Network.
site are ∼26 kb apart. The SNP maps with the APOA2 proximal
promoter region, and there is some evidence to indicate that the
CpG is within an enhancer (27). Thus, it is plausible to hypothe-
size that elevated intake of SFA serves to promote a looping of the
DNA between these 2 regions, providing a means by which they
can interact functionally. This interaction would have a stronger
effect on APOA2 expression only with the CC genotype at rs5082
and under conditions of high intake of SFA.
CpG methylation and APOA2 genotype are associated with
APOA2 mRNA expression, depending on SFA intake
As epigenetic status can affect expression of targeted genes,
we determined if the identified methylation site in the APOA2
region was associated with APOA2 mRNA expression. To do
this, we examined the correlation between cg04436964 methy-
lation and mRNA expression in whole blood for the 31 protein-
and RNA-coding genes located within 50 kb of this CpG site
by mining transcriptome data from FHS exam 8. Among the 31
genes, mRNA expression of 10 genes was detected and passed
QC (see Supplemental Table 1). For participants with high-SFA
intake, cg04436964 methylation exhibited a negative and sig-
nificant association (Figure 4B, β = −0.891, P = 0.028) with
APOA2 mRNA expression. In contrast, those with low-SFA in-
take, APOA2 mRNA expression was not associated with methy-
lation at cg04436964 (Figure 4A, β = 0.091, P = 0.857). The
results remained the same even after adjusting for the additional
potential confounder BMI.
Further, we observed an association between APOA2 −265T
>C genotype and APOA2 mRNA expression that resembled the
association which links methylation and expression, in that the
2 associations were limited to participants with high-SFA intake
(Figure 5). Among participants with high-SFA intake, we saw
that CC homozygotes had significantly lower APOA2 expression
than TT homozygotes [mean expression: 5.79 (CC) compared
with 5.90 (TT), P = 0.010]. In contrast, among participants with
low-SFA intake, there was no significant difference in APOA2 ex-
pression between CC and TT genotypes [mean expression: 5.86
(CC) compared with 5.84 (TT), P = 0.670].
In participants with a high-SFA diet, there is no correlation be-
tweenAPOA2 expression and expression ofNDUFS2 (P= 0.775)
or ADAMTS4 (P = 0.699). Hence, under a high-SFA diet, there
is no influence of expression of the 2 genes on APOA2 ex-
pression. It is possible that the CpG cg04436964 participates in
regulating the expression of other genes in tissues other than
peripheral blood cells. However, biologically relevant tissues,
including liver, subcutaneous and visceral adipose, and kid-
ney, were not readily available for such analysis, especially
with regard to APOA2 genotype and saturated fat intake.
Lastly, mining Genotype-Tissue Expression Project data (ver-
sion 7) shows a weak expression quantitative trait locus for
−265T>C in liver and subcutaneous adipose for TOMM40L,
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FIGURE 4 Correlation between APOA2 mRNA expression in whole
blood and methylation at cg04436964 in the FHS at exam 8. (A) Under
low saturated fat intake or <22 g/d (low-SFA), (B) under high saturated fat
intake or ≥22 g/d (high-SFA). The y-axis displays a normalized and log2-
transformed signal of APOA2 mRNA expression adjusted for age, gender,
and heterogeneity of cell type, whereas the x-axis displays the methylation
level of cg04436964. APOA2, apolipoprotein A-II; FHS, Framingham Heart
Study.
than the APOA2 TSS. However, TOMM40L expression in blood
did not correlate with cg04436964 methylation (Supplemental
Table 1).
High-SFA intake highlights metabolic differences between
APOA2 genotypes
To examine the metabolic differences between CC and TT
genotypes, metabolic pathway enrichment analysis was per-
formed separately for low- and high-SFA intake datasets, with
adjustment for BMI in the analysis. Among 808 metabolites
detected in 80 plasma samples from the BPRHS, 635 com-
pounds were grouped into 63 metabolic pathways, each of which
contained ≥3 metabolites. Comparing CC to TT carriers on the
low-SFA diet, 23 and 26metabolites showed significant increases
and decreases at P≤ 0.05 (Supplemental Table 2), respectively.
Comparing CC to TT carriers under high-SFA conditions, 7 and
64 metabolites displayed significant increases and decreases at
P ≤ 0.05 (Supplemental Table 2), respectively. Metabolites that
differed between CC and TT genotypes at P≤ 0.05 were counted
within each pathway (Supplemental Table 3). For low-SFA
intake, there were 4 pathways with a z score of ≥1.96 (P≤ 0.05),
but none passed significance after correction for multiple testing
(P = 0.05/63 = 0.0008 for 63 pathways). For high-SFA intake,
6 pathways had a z score of ≥1.96 (P ≤ 0.05). After correc-
tion for multiple testing, 4 pathways remained significantly
overrepresented (Supplemental Table 3): leucine, isoleucine,
and valine metabolism (P = 2.00 × 10−6), monoacylglyc-
erol metabolism (P = 7.94 × 10−5), tryptophan metabolism
(P = 0.0003), and phenylalanine metabolism (P = 0.0005).
These 4 pathways highlight important metabolic differences
between APOA2 genotypes (CC vs. TT) with a high-SFA intake.
Linking the epigenomic signature of the APOA2-SFA
interaction and the metabolic network
To characterize the connections between the epigenomic
signature and the metabolic network, we conducted metabolic
pathway enrichment analysis to investigate differential methy-
lation between APOA2 genotypes with high-SFA intake. We
examined the correlation between methylation at cg04436964
and 635 metabolites in 63 pathways. The cg04436964-associated
(at P ≤ 0.05) metabolites were merged with those that differed
(at P ≤ 0.05) between CC and TT genotypes under a high-SFA
intake. Eighteen metabolites met both criteria, as their levels
in blood demonstrated association with cg04436964 methyla-
tion at P ≤ 0.05 and differed between CC and TT genotypes
under high-SFA intake (Supplemental Table 4). Enrichment
analysis with correction for multiple testing identified 2 path-
ways as being significantly enriched: tryptophan metabolism
(Supplemental Table 4, Z= 5.029, P= 4.92× 10−7) and leucine,
isoleucine, and valine metabolism, also called branched-chain
amino acid (BCAA)metabolism (z= 4.048,P= 5.16× 10−5). In
the tryptophan metabolism pathway (Figure 6), 6 of 18 detected
metabolites (33%) were correlated with cg04436964 methyla-
tion. In CC carriers, 4 of those metabolites, 3-indoxyl sulfate,
indolelactate, indoleacetyl glutamine, and xanthurenate, were at
lower concentrations than in TT carriers under high-SFA intake.
In the BCAAmetabolism pathway, 10 of 25metabolites (40%)
displayed negative correlation with methylation of cg04436964,
4 of which differed between CC and TT genotypes with high-
FIGURE 5 Box plot of APOA2 mRNA expression according to APOA2
–265T >C (rs5082) genotypes in the FHS at exam 8. The cyan box indicates
participants with the CC genotype and the magenta box is for participants
with the TT genotype, not taking medication for hypertension, dyslipidemia,
or diabetes. Inside the box, the empty circle indicates means and the hori-
zontal lines are medians. The bottom and top edges of the box indicate the
range of values between the first and third quartiles (the 25th and 75th per-
centiles), whereas whiskers indicate the data range outside the box. Beyond
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FIGURE 6 CC homozygotes display perturbations in the tryptophan metabolism pathway. The metabolites highlighted in green were significantly
(P < 0.05) decreased in CC genotype (cyan box) when compared with TT genotype (magenta box) with high-SFA intake. Box plots of 4 metabolites that
met 2 criteria—1) differed between CC and TT genotypes, and 2) was associated with cg04436964—were shown according to APOA2 genotypes and SFA
intakes. Inside the box, the empty circle indicates means and the horizontal lines are medians. The bottom and top edges of the box indicate the range of values
between the first and third quartiles (the 25th and 75th percentiles), whereas whiskers indicate the data range outside the box. Beyond the whiskers are the
outliers.
SFA intake: α-hydroxyisocaproate, β-hydroxyisovalerate, 2-
methylbutyrylcarnitine, and 3-hydroxy-2-ethylpropionate. Taken
together, these observations of altered metabolite levels imply
that with high-SFA intake, tryptophan metabolism and BCAA
metabolism are reduced to a greater extent in CC carriers than
in TT carriers.
DISCUSSION
A high-SFA diet can synergistically augment the risk of
obesity for individuals with a particular genotype or portfolio
of risk-increasing alleles (31, 32). The mechanisms by which
such gene-diet interactions manifest their effects on obesity are
not well characterized. In several populations encompassing
various ancestries, we have demonstrated a gene-diet interaction
whereby APOA2 CC homozygotes at −265T>C exhibited an
increased risk of obesity when consuming a diet high in SFA
compared with TT carriers (3–7), but they (CC homozygotes)
had no increased risk of obesity when consuming a low-SFA
diet (4–8). Thus, this replicated interaction between APOA2
genotype and SFA provides a useful platform for dissecting and
characterizing the mechanisms of a gene-by-diet interaction on
obesity. To achieve this objective, we report methylome, tran-
scription, and metabolomics analyses based on 3 populations.
We showed that participants with the CC genotype and high-
SFA intake had increased methylation at cg04436964, near the
APOA2 gene, compared with TT carriers, echoing the differences
in BMI that have been replicated in 6 populations (3–7). Just
as BMI did not differ by −265T>C genotype with low-SFA
intake, genotype-based differences in methylation were also less
apparent when SFA intake was low. The current study broadens
our understanding, in that increased methylation at cg04436964
is associated with decreased expression of APOA2, again under
high-SFA intake conditions. Both the methylation differences
and the altered gene expression reflect the signals of the gene-diet
interaction between APOA2 genotype and dietary SFA intake.
A comparison of the metabolomic profiles for CC and TT
genotypes in the BPRHS for high-SFA intake, but not for low-
SFA intake, identified 4 metabolic pathways that were signifi-
cantly overrepresented: phenylalanine, monoacylglycerol, tryp-
tophan, and BCAA. These results suggest that key differences
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explained by the metabolism of lipids and amino acids. We
further demonstrated that the correlation between cg04436964
methylation and genotype-specific metabolites was significantly
enriched in 2 of these pathways, namely tryptophan metabolism
and BCAA metabolism. This indicates that, under conditions of
elevated intake of SFA, CC carriers have dysregulated tryptophan
metabolism and BCAA pathways to a greater degree than do TT
carriers.
In mammals, tryptophan metabolism is a powerful regulator of
feeding and satiety (33, 34). Over 95% of tryptophan is metab-
olized through the kynurenine pathway (35, 36). While plasma
serotonin cannot enter the brain, kynurenine easily passes the
blood-brain barrier. Thus, plasma kynurenine concentration re-
liably reflects the status in brain of kynurenic acids or kynure-
nate (35). Recently, kynurenic acid has been characterized as reg-
ulating food-dependent behavioral plasticity in Caenorhabditis
elegans via a system whose elements are conserved with mam-
mals (37). Fasting depletes kynurenic acid, and low kynurenic
acid activates NMDA-receptor-expressing interneurons to pro-
mote food cravings through a neuropeptide-Y-like signaling axis
and serotonin release upon feeding (37). In our study, under a
high-SFA diet, CC carriers exhibited reduced concentrations of
tryptophan metabolites in the kynurenine pathway (Figure 6), in-
cluding xanthurenate and kynurenic acid, relative to TT carriers.
Appetite in CC carriers would then be expected to be greater
than in TT carriers, hence CC individuals would consume more
food. Indeed, CC carriers, in general, consume more kilocalories
than TT carriers (4, 5), which elevates their obesity risk. Further-
more, CC individuals also showed low levels of 3-indoxyl sul-
fate, indolelactate, and indoleacetyl glutamine, perhaps indicat-
ing reduced doleamine-2,3-dioxygenase-independent tryptophan
catabolism (35). Lastly, associations between eating behavior and
variants in genes encoding monoamine oxidase A and serotonin
receptor 2A underscore the role of the tryptophan-serotonin-
kynurenine pathway in appetite (38). Thus, altering tryptophan
catabolism can lead to an imbalance between energy intake and
expenditure via impact on appetite, thereby augmenting the risk
of obesity.
In the enriched BCAA metabolism pathway, where metabo-
lites differed between CC and TT genotypes and were
associated with cg04436964 methylation and APOA2 ex-
pression, CC homozygotes with high-SFA intake uniquely
showed a decrease of 4 BCAA catabolites: 3-hydroxy-2-
ethylpropionate, α-hydroxyioscaproate, β-hydroxyisovalerate,
and 2-methylbutyrylcarnitine. Impaired flux through the BCAA
metabolic pathway is a sign of overall metabolic inefficiency.
Specifically, with high-fat diets, reduced flux through the BCAA
metabolic pathwaywas associatedwith obesity onset inmini-pigs
(39), hindering BCAA-driven modulation of glucose metabolism
in the liver, thereby elevating insulin resistance (40). Further-
more, when the metabolic capacity of the liver is compromised
by high-fat feeding, BCAA homeostasis is less stably main-
tained, and this impairs the liver-skeletal muscle axis of coop-
erative BCAA catabolism (41). In parallel, defects in BCAA ox-
idation in muscle serve to disrupt normal lipid metabolism (42),
possibly by curbing mTOR-mediated mitochondrial biogenesis
(43), which could be of greater effect with high-SFA intakes. To-
gether, the observed changes in metabolites within the Trp/KynA
and BCAA pathways, examined in conjunction with reduced
succinyl carnitine of the TCA cycle (Supplemental Table 2), serve
as dual indicators of altered signaling—appetite/feeding and en-
ergy balance—that promote the development of obesity.
Our application of omics in 3 populations is a major strength
of this study. Beginning with the multiancestral BPRHS, we ini-
tially detected methylation differences between APOA2 geno-
type in participants with high-SFA intake, examining 20 par-
ticipants of CC genotype and 20 participants of TT geno-
type. One may argue that the small sample size of the BPRHS
discovery cohort limits the power to identify other methylation
sites that are associated with the APOA2 genotype differentially
under low- and high-SFA intake. However, we have validated our
findings by conducting 2 additional epigenome-wide associations
in the FHS and GOLDN populations. Three methylation sites—
cg04436964, cg24429974, and cg24847046—were identified at
the threshold of epigenome-wide significance after correction for
multiple testing. Meta-analysis of these results confirmed that
only the methylation at cg04436964 differed between APOA2
genotypes and correlated with APOA2 mRNA under high-SFA
intake. CC carriers with high-SFA intake tend to have high BMI,
so obesity may be contributing to the differences in epigenetic
status. Throughout our analyses, we have controlled for BMI in
all 3 populations and the results remain consistent. In the FHS,
we observed a significant difference in cg04436964 methylation
between CC and TT carriers with low-SFA intake, which was not
observed in the BPRHS or the GOLDN Study. Detection of the
difference in the FHS alone cannot be attributed to greater power
stemming from greater sample size because the sample size was
greatest in the GOLDN Study. Instead, our ability to detect the
difference in the FHS could be explained by the possibility that
CC carriers modified SFA intake over time, i.e., some partici-
pants might have consumed higher SFA intake early and then
changed to a low-SFA diet at a later time point. Indeed, when
we examined the SFA intake across 4 examinations—exams 5–
8 of the FHS—we found that only 15 CC (6.2%) and 24 TT
(9.9%) carriers of 243 participants (without taking medications
for lowering lipids, diabetes and hypertension)maintained a high-
SFA diet (≥22 g/d) (3, 6), whereas 23 CC (9.5%) and 38 TT
(15.6%) carriers maintained a low-SFA diet (<22 g/d) across all
4 exams. An epigenome-wide scan with 23 CC and 38 TT par-
ticipants with consistent low-SFA intake across all 4 exams in-
dicated that the difference in cg04436964 methylation between
CC and TT genotypes did not reach epigenome-wide significance
(P = 1.7 × 10−6 > 1.1 × 10−7). On the other hand, for 15 CC
and 24 TT participants with consistent high-SFA intake across
all 4 exams, the difference in cg04436964 methylation between
CC and TT genotypes did reach epigenome-wide significance
(P = 4.11 × 10−11). This observation further confirms that the
SFA-dependent cg04436964methylation differs between CC and
TT genotypes consistently in all 3 distinct populations.
Some limitations of the current study must be noted. First,
the epigenome analysis of the GOLDN Study used CD4 + T
cells from a frozen buffy coat, whereas the BPRHS and FHS
analyses were conducted using whole-blood buffy coats. This
difference could introduce inconsistencies in estimating the
population-specific effect sizes associated with methylation. In-
deed, the β value for methylation associated with the C-allele
was smaller in the GOLDN Study than in the BPRHS and FHS,
but the directions were consistent in all cohorts. Second, the di-
etary patterns and food sources of SFA and their corresponding
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and cultural differences. In this regard, the BPRHS,which studied
a population of Caribbean Hispanic origin, is quite different from
the FHS and the GOLDN Study. Population level differences in
lifestyle, including diet, could also contribute to epigenetic differ-
ences between populations. Lastly, although we employed a tar-
geted metabolomics approach, this is inherently limited to those
metabolites that have been identified.
In summary, we applied multiomics approaches to investi-
gate the mechanistic foundations of one of the most consistently
replicated gene-diet interactions, that of SFA and the APOA2
genotype. Our findings from 3 populations of diverse ancestries
strongly support that the epigenetic status of the APOA2 reg-
ulatory region is associated with SFA intake and the APOA2
−265T>C genotype, leading to differential diet-dependent and
genotype-dependent APOA2 expression. As appropriate for a
gene-diet interaction linked to the disruptive condition of obesity,
we also uncovered plausible dysregulation of select metabolic
pathways. The epigenetic signature of the gene-diet interaction is
correlated with the down-regulation of the kynurenine pathway
of tryptophan metabolism and BCAA metabolism, with possible
implications for food intake. Collectively, these findings illustrate
the effectiveness of multiomic approaches to well-established
gene-diet interactions, and contribute novel evidence to ongoing
explorations of the impact of saturated fat on human health.
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